Biomarkers in transthyretin amyloidosis. Present and future

The appearance of new treatments for the different forms of ATTR has highlighted the importance of early diagnosis, since most of these treatments are highly effective in the initial phases of the disease. Currently, the diagnosis of ATTR is fundamentally based on clinical findings, cardiac imaging and neurophysiological parameters, and it is common a delay in diagnosis, and this occurs very frequently in advanced phases of the disease. The appearance of different biomarkers attempts to promote early diagnosis, as well as stratify into different risk groups, which can benefit from specific treatments, as well as obtain prognostic data from patients. This article reviews the different biomarkers currently available in ATTR and potential future biomarkers.